Harvard Bioscience (HBIO) Misses Q4 EPS by 1c, provides guidance

Harvard Bioscience (NASDAQ: HBIO) reported Q4 EPS of $0.04, $0.01 worse than the analyst estimate of $0.05. Revenue for the quarter came in at $28.2 million versus the consensus estimate of $29.1 million.

2024 Guidance:

For the full year 2024 we expect flat to modest revenue growth. We expect weakness in the first half versus a strong prior year comparison. We also expect strong second half growth versus both first half of 2024 and second half of 2023, supported by new product commercializations and expected improvements in Chinese market conditions. In addition, we expect further gross margin expansion in the full year 2024 to approximately 60% compared to 59% in 2023 and adjusted EBITDA margin improving to the mid-teens compared to 13% in 2023.

For earnings history and earnings-related data on Harvard Bioscience (HBIO) click here.

You May Also Be Interested In

• Barrick Mining said to delay IPO of American gold business to 2027
• Snowflake (SNOW) Tops Q2 EPS by 17c, Offers Guidance
• NetApp (NTAP) Tops Q1 EPS by 47c, Beats on Revenue